Press Releases InMed Receives CTA Approval for Second Phase 1 Clinical Trial with INM-755 April 30, 2020 Read More » InMed Announces Completion of Initial Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects April 1, 2020 Read More » InMed Submits Clinical Trial Application to Evaluate INM-755 in Second Phase 1 Trial March 24, 2020 Read More » InMed Provides Update on Operations in Response to the COVID-19 Global Outbreak March 20, 2020 Read More » InMed Pharmaceuticals Announces Completed Enrollment in Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects March 10, 2020 Read More » InMed Pharmaceuticals Reports Second Quarter Fiscal 2020 Financial Results and Provides R&D and Business Update February 14, 2020 Read More » InMed Pharmaceuticals to Report Second Quarter Fiscal 2020 Financial Results and Business Update on February 14, 2020 February 7, 2020 Read More » InMed Expands on Announcement of Cannabinol (CBN) Therapeutic Leadership with New Website Content and CEO Interview January 21, 2020 Read More » InMed First to Advance Cannabinol (CBN) into Therapeutic Clinical Trials January 20, 2020 Read More » InMed Pharmaceuticals to Attend and Exhibit at EB2020 World Congress January 16, 2020 Read More » InMed Announces Election of Directors January 10, 2020 Read More » InMed Pharmaceuticals to Present at the Biotech Showcase Conference January 8, 2020 Read More » InMed Receives Clinical Trial Application Approval for INM-755, a Rare Cannabinoid Formulation Under Development for the Treatment of Epidermolysis Bullosa December 9, 2019 Read More » InMed Pharmaceuticals to Present at the Cowen Conference November 11, 2019 Read More » InMed Pharmaceuticals Reports First Quarter Fiscal 2020 Financial Results and Provides R&D and Business Update November 8, 2019 Read More » InMed Submits Clinical Trial Application to Evaluate INM-755 in Phase 1 Trial November 5, 2019 Read More » InMed Pharmaceuticals to Report First Quarter Fiscal 2020 Financial Results and Business Update on November 8, 2019 November 4, 2019 Read More » InMed Pharmaceuticals to Present at the BIO Investor Forum October 18, 2019 Read More » InMed Pharmaceuticals to Present at the Regulatory Affairs Professionals Society’s annual conference September 23, 2019 Read More » InMed Pharmaceuticals Reports Fourth Quarter and Full Year Fiscal 2019 Financial Results and Provides R&D and Business Update September 19, 2019 Read More » « Previous Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Page13 Page14 Next » Management Learn More Board of Directors Learn More Scientific Advisory Board Learn More Investor Alerts Sign up to receive news releases from InMed Pharmaceuticals. SIGN UP
InMed Receives CTA Approval for Second Phase 1 Clinical Trial with INM-755 April 30, 2020 Read More »
InMed Announces Completion of Initial Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects April 1, 2020 Read More »
InMed Submits Clinical Trial Application to Evaluate INM-755 in Second Phase 1 Trial March 24, 2020 Read More »
InMed Provides Update on Operations in Response to the COVID-19 Global Outbreak March 20, 2020 Read More »
InMed Pharmaceuticals Announces Completed Enrollment in Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects March 10, 2020 Read More »
InMed Pharmaceuticals Reports Second Quarter Fiscal 2020 Financial Results and Provides R&D and Business Update February 14, 2020 Read More »
InMed Pharmaceuticals to Report Second Quarter Fiscal 2020 Financial Results and Business Update on February 14, 2020 February 7, 2020 Read More »
InMed Expands on Announcement of Cannabinol (CBN) Therapeutic Leadership with New Website Content and CEO Interview January 21, 2020 Read More »
InMed First to Advance Cannabinol (CBN) into Therapeutic Clinical Trials January 20, 2020 Read More »
InMed Receives Clinical Trial Application Approval for INM-755, a Rare Cannabinoid Formulation Under Development for the Treatment of Epidermolysis Bullosa December 9, 2019 Read More »
InMed Pharmaceuticals Reports First Quarter Fiscal 2020 Financial Results and Provides R&D and Business Update November 8, 2019 Read More »
InMed Submits Clinical Trial Application to Evaluate INM-755 in Phase 1 Trial November 5, 2019 Read More »
InMed Pharmaceuticals to Report First Quarter Fiscal 2020 Financial Results and Business Update on November 8, 2019 November 4, 2019 Read More »
InMed Pharmaceuticals to Present at the Regulatory Affairs Professionals Society’s annual conference September 23, 2019 Read More »
InMed Pharmaceuticals Reports Fourth Quarter and Full Year Fiscal 2019 Financial Results and Provides R&D and Business Update September 19, 2019 Read More »